# Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women

> **NCT05457894** · PHASE3 · COMPLETED · sponsor: **St. Petersburg Research Institute of Vaccines and Sera** · enrollment: 207 (actual)

## Conditions studied

- Influenza, Human
- Vaccination; Infection
- Vaccines

## Interventions

- **BIOLOGICAL:** Flu-M, Inactivated split influenza vaccine
- **BIOLOGICAL:** Ultrix®, Inactivated Split Influenza Vaccine

## Key facts

- **NCT ID:** NCT05457894
- **Lead sponsor:** St. Petersburg Research Institute of Vaccines and Sera
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-23
- **Primary completion:** 2021-03-11
- **Final completion:** 2021-07-26
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2022-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05457894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05457894, "Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05457894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*